Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...
Editor's note: This story was updated at 1225p ET on Feb. 21 with comment from Eli Lilly. Several individuals ... also come with its share of notable side effects. Speaking with several trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results